Seasonal affective disorder (SAD) is a mood disorder subset in which people who have normal mental health throughout most of the year exhibit depressive symptoms at the same time each year, most commonly in the winter. Common symptoms include sleeping too much, having little to no energy, and overeating. The condition in the summer can include heightened anxiety.
This report contains market size and forecasts of Seasonal Affective Disorder Therapeutics in Global, including the following market information:
Global Seasonal Affective Disorder Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Seasonal Affective Disorder Therapeutics market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Light Therapy (Phototherapy) Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Seasonal Affective Disorder Therapeutics include Allergan, Pfizer, Roche, Eli Lily, GlaxoSmithKline, Teva Pharmaceuticals, Bausch Health Companies, Mylan and Sanofi, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Seasonal Affective Disorder Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Seasonal Affective Disorder Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Seasonal Affective Disorder Therapeutics Market Segment Percentages, by Type, 2021 (%)
Light Therapy (Phototherapy)
Medication
Others
Global Seasonal Affective Disorder Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Seasonal Affective Disorder Therapeutics Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Seasonal Affective Disorder Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Seasonal Affective Disorder Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Seasonal Affective Disorder Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Seasonal Affective Disorder Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Allergan
Pfizer
Roche
Eli Lily
GlaxoSmithKline
Teva Pharmaceuticals
Bausch Health Companies
Mylan
Sanofi
Novartis
Johnson & Johnson
Koninklijke Philips
Beurer GmbH
Lucimed (Luminette)